Cerus (NASDAQ:CERS – Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Cerus to post earnings of ($0.03) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Cerus (NASDAQ:CERS – Get Free Report) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The business had revenue of $45.08 million for the quarter, compared to the consensus estimate of $42.50 million. During the same quarter in the previous year, the business earned ($0.07) earnings per share. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cerus Stock Performance
Shares of NASDAQ CERS opened at $1.63 on Wednesday. The stock has a market capitalization of $301.37 million, a PE ratio of -9.59 and a beta of 1.18. Cerus has a 52 week low of $1.23 and a 52 week high of $2.59. The stock has a 50 day moving average price of $1.96 and a 200 day moving average price of $1.92. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.83 and a current ratio of 2.51.
Insider Buying and Selling at Cerus
Analyst Upgrades and Downgrades
Separately, Stifel Nicolaus lowered their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Cerus has an average rating of “Moderate Buy” and an average price target of $3.63.
Get Our Latest Analysis on Cerus
Cerus Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Further Reading
- Five stocks we like better than Cerus
- About the Markup Calculator
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Fintech Stocks With Good 2021 Prospects
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.